The LATAM Generic Drug Playbook: Patent Cliffs, Regulatory Arbitrage, and Why Most Multinationals Get It Wrong
The LATAM Generic Drug Playbook: Patent Cliffs, Regulatory Arbitrage, and Why Most Multinationals Get It Wrong The Latin American generic
Insights
Biopharma Patent Intelligence: The Definitive Guide to Turning IP Data into Pipeline and Deal Advantage
Part 1: The Economics of Biopharma Risk: Why Standard Research Isn’t Enough The cost to bring a new molecular entity
Drug Exclusivity Decoded: The Complete Playbook for Maximum Market Protection
Introduction: The Patent Cliff Is Yesterday’s Problem The pharmaceutical industry spent decades obsessing over the patent cliff, that moment when
Drug Exclusivity Decoded: The Complete Playbook for Maximum Market Protection Read Post »
Drug Patent IP Valuation & Financing: The Definitive Analyst’s Playbook
How to quantify pharmaceutical patent assets, structure patent-backed financing, and convert exclusivity data into investment-grade capital strategies 1. Why Pharma
Drug Patent IP Valuation & Financing: The Definitive Analyst’s Playbook Read Post »
Drug Patent API Data Feeds: The Formulary Automation Playbook for Payers, Providers, and Pharmacies
Formulary management is a nine-figure business problem dressed up as a clinical workflow. Every Pharmacy & Therapeutics (P&T) committee in
Score Patentability Before R&D Commits: The AI Pharma IP Stack That Turns Patent Risk into Portfolio Alpha
Part I: The Strategic Imperative – Patent Risk as a Financial Variable {#part-i} The $2.6 Billion Problem No Pipeline Model
Amgen v. Sanofi: The Definitive Technical Playbook on Biologic Patent Enablement, Antibody Claim Strategy, and the Biosimilar Challenger’s Advantage
1. The Patent Bargain, Recalibrated: What the Ruling Actually Did On May 18, 2023, the U.S. Supreme Court issued a
Pharma IP Benchmarking: The Complete Playbook for Protecting Pipeline Value Before a Competitor Does
Why IP Benchmarking Is a Revenue Function, Not a Legal One A composition of matter patent on a new drug
Unveiling the Secrets Behind Big Pharma’s Patent Thickets
Section 1: The Broken Bargain: How a 20-Year Monopoly Became a 40-Year Rent The patent system’s foundational premise is blunt:
Unveiling the Secrets Behind Big Pharma’s Patent Thickets Read Post »
